261 related articles for article (PubMed ID: 21982144)
1. Comparative randomised clinical trial against glycopeptides supports the use of daptomycin as first-line treatment of complicated skin and soft-tissue infections.
Quist SR; Fierlbeck G; Seaton RA; Loeffler J; Chaves RL
Int J Antimicrob Agents; 2012 Jan; 39(1):90-1. PubMed ID: 21982144
[No Abstract] [Full Text] [Related]
2. Retrospective case-control analysis of patients with staphylococcal infections receiving daptomycin or glycopeptide therapy.
Falcone M; Russo A; Pompeo ME; Vena A; Marruncheddu L; Ciccaglioni A; Grossi P; Mancini C; Novelli A; Stefani S; Venditti M
Int J Antimicrob Agents; 2012 Jan; 39(1):64-8. PubMed ID: 22047703
[TBL] [Abstract][Full Text] [Related]
3. Daptomycin: rationale and role in the management of skin and soft tissue infections.
Seaton RA
J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii15-23. PubMed ID: 18829721
[TBL] [Abstract][Full Text] [Related]
4. Caution when reconsidering empiric antimicrobial therapy for methicillin-resistant Staphylococcus aureus skin and soft-tissue infections.
da Silva LV; Zavascki AP; de Souza MV; Marcadenti A
Am J Surg; 2008 Oct; 196(4):618-9. PubMed ID: 18809069
[No Abstract] [Full Text] [Related]
5. [Daptomycin--a new antibiotic for the treatment of skin and soft tissue infections].
Mathiesen L; Midtvedt T; Solberg CO
Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2383-4. PubMed ID: 16998552
[TBL] [Abstract][Full Text] [Related]
6. Treatment of staphylococcal infections with cyclic lipopeptides.
Eisenstein BI
Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():10-6. PubMed ID: 18226085
[TBL] [Abstract][Full Text] [Related]
7. Serious staphylococcal infections--cyclic lipopeptides: meeting new challenges.
Graninger W
Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():1-2. PubMed ID: 18226083
[No Abstract] [Full Text] [Related]
8. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).
Itani KM; Weigelt J; Li JZ; Duttagupta S
Int J Antimicrob Agents; 2005 Dec; 26(6):442-8. PubMed ID: 16289514
[TBL] [Abstract][Full Text] [Related]
9. Weight-based antibiotic dosing in a real-world European study of complicated skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus.
Lawson W; Nathwani D; Eckmann C; Corman S; Stephens J; Solem C; Macahilig C; Li J; Baillon-Plot N; Charbonneau C; Haider S
Clin Microbiol Infect; 2015 Sep; 21 Suppl 2():S40-6. PubMed ID: 26206621
[TBL] [Abstract][Full Text] [Related]
10. Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes.
Davis SL; McKinnon PS; Hall LM; Delgado G; Rose W; Wilson RF; Rybak MJ
Pharmacotherapy; 2007 Dec; 27(12):1611-8. PubMed ID: 18041881
[TBL] [Abstract][Full Text] [Related]
11. Treatment of skin and soft tissue infections due to community-associated methicillin-resistant Staphylococcus aureus in Europe: the role of trimethoprim-sulfamethoxazole0010.
De Angelis G; Cipriani M; Cauda R; Tacconelli E
Clin Infect Dis; 2011 Jun; 52(12):1471-2; author reply 1472. PubMed ID: 21628490
[No Abstract] [Full Text] [Related]
12. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.
Daum RS
N Engl J Med; 2007 Jul; 357(4):380-90. PubMed ID: 17652653
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of intravenous daptomycin in Japanese patients with skin and soft tissue infections.
Aikawa N; Kusachi S; Mikamo H; Takesue Y; Watanabe S; Tanaka Y; Morita A; Tsumori K; Kato Y; Yoshinari T
J Infect Chemother; 2013 Jun; 19(3):447-55. PubMed ID: 23085743
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections.
Logman JF; Stephens J; Heeg B; Haider S; Cappelleri J; Nathwani D; Tice A; van Hout BA
Curr Med Res Opin; 2010 Jul; 26(7):1565-78. PubMed ID: 20429820
[TBL] [Abstract][Full Text] [Related]
15. Emerging drugs for complicated skin and skin-structure infections.
Mendoza N; Tyring SK
Expert Opin Emerg Drugs; 2010 Sep; 15(3):509-20. PubMed ID: 20557269
[TBL] [Abstract][Full Text] [Related]
16. European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid.
Bassetti M; Baguneid M; Bouza E; Dryden M; Nathwani D; Wilcox M
Clin Microbiol Infect; 2014 Apr; 20 Suppl 4():3-18. PubMed ID: 24580738
[TBL] [Abstract][Full Text] [Related]
17. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus.
Stryjewski ME; Chambers HF
Clin Infect Dis; 2008 Jun; 46 Suppl 5():S368-77. PubMed ID: 18462092
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility of Staphylococcus aureus to vancomycin: analysis of minimum inhibitory concentrations in two tertiary care hospitals in eastern South Dakota.
Laible BR; Hellwig TR; Hedge DD
S D Med; 2011 Mar; 64(3):91-5. PubMed ID: 21473519
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of linezolid in methicillin-resistant Staphylococcus aureus skin and skin structure infections.
Bounthavong M; Hsu DI
Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):683-98. PubMed ID: 23252352
[TBL] [Abstract][Full Text] [Related]
20. Daptomycin for soft tissue infection and neutropenia in a myelogenous leukemia patient who failed prior vancomycin therapy.
Sakoulas G
Clin Adv Hematol Oncol; 2008 Nov; 6(11):813-5. PubMed ID: 19194364
[No Abstract] [Full Text] [Related]
[Next] [New Search]
